BrainStorm Cell Therapeutics Announces Peer Reviewed Publication of Results from the NurOwn(R) Phase 2 Progressive MS Trial in Multiple Sclerosis Journal

Data demonstrate NurOwn's safety and provide preliminary evidence of efficacy in patients with progressive multiple sclerosis Biomarker analyses show consistent treatment effects in neuroinflammation and neuroprotection pathways NEW YORK, Sept. 15, 2... Regenerative Medicine, Neurology BrainStorm Cell Therapeutics, NurOwn, multiple sclerosis, stem cell
Source: HSMN NewsFeed - Category: Pharmaceuticals Source Type: news